DrugDashboards

Natesto nasal gel

testosterone · TESTOSTERONE 5.5 mg/.122g · Gel, Metered · Nasal · Acerus Pharmaceuticals Corporation

NDC 42667-5511-01 · 1 APPLICATOR in 1 BOX / 11 g in 1 APPLICATOR · NDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The brand price has held steady around $41.28 per gram over the past year. Generic versions run $0.4717 per gram88× cheaper. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$41.28per GMinvoice-surveyed acquisition cost · Jul 22, 2026
  • Part D plans paid (avg)$38.41per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$38.10per unitnegotiated price across 11 plans — before rebates · Jul 1, 2024

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$38.10per unit
middle half $37.76$38.10 · 11 plans · Jul 1, 2024
Est. net of rebates
$22.86–$28.58
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 3 quarters since 2024.

NADAC price per unit

$0$20.00$40.00$60.00May 2022Sep 2026$41.28
27 price points · per GM · held since Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$315.40
Reported to Texas DSHS · 2026 annual filing · Acerus Pharmaceuticals Corporation Acerus PAcerus Pharmaceuticals Corporationharmaceuticals Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$8,597
12 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for testosterone (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA205488
TE code
Approval date
May 28, 2014
Patents / exclusivity
2 patents, 0 exclusivities
TypeNumber / codeExpires
patent11744838Mar 17, 2034
patent11090312Mar 17, 2034

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of testosterone (Gel, Metered)

LabelerStrengthFirst seenLast seen
Upsher-Smith Laboratories, LLCTESTOSTERONE 12.5 mg/1Jul 15, 2026Sep 3, 2026
Acerus Pharmaceuticals CorporationTESTOSTERONE 5.5 mg/.122gJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCTESTOSTERONE 20.25 mg/1.25gJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories, Inc.TESTOSTERONE 1.62 mg/gJul 15, 2026Sep 2, 2026
Northstar Rx LLCTESTOSTERONE 20.25 mg/1.25gJul 15, 2026Sep 2, 2026
Xiromed, LLCTESTOSTERONE 20.25 mg/1.25gJul 15, 2026Sep 2, 2026
Bryant Ranch PrepackTESTOSTERONE 20.25 mg/1.25gJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Natesto nasal gel — NDC 42667-5511-01," retrieved September 3, 2026, https://drugdashboards.com/drug/42667551101.

Free to cite with attribution — see how the data is put together.